Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Anticancer Drugs
; 31(6): 652-654, 2020 07.
Article
em En
| MEDLINE
| ID: mdl-32011367
ABSTRACT
Mucosal melanoma is rare and accounts for 1.3-1.4% of all melanomas. Kit mutations are found in approximately 15-20% of mucosal melanomas. Immunotherapy with anti cytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death protein 1 have reported low clinical efficacy in this melanoma subtype. Studies with Kit inhibitor Imatinib showed response rates ranging from 20 to 30%. We present the case of a patient with a c-kit mutated metastatic melanoma who developed autoimmune vitiligo during treatment with oral tyrosine kinase inhibitor Masitinib.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tiazóis
/
Vitiligo
/
Neoplasias Vulvares
/
Proteínas Proto-Oncogênicas c-kit
/
Melanoma
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article